1 week ago
Metropolis Healthcare Q2 Results | The diagnostic service provider reported a 31% YoY surge in net profit at ₹46.5 crore. Shares of Metropolis Healthcare Ltd ended at ₹2,116.95, up by ₹4.35, or 0.21%, on the BSE.
Diagnostic service provider Metropolis Healthcare Ltd on Friday (November 8) reported a 31% year-on-year (YoY) surge in net profit at ₹46.5 crore for the second quarter that ended on September 30, 2024.
In the corresponding quarter of the previous fiscal, Metropolis Healthcare posted a net profit of ₹35.5 crore, the company said in a regulatory filing. Revenue from operations increased 13.4% to ₹349.8 crore against ₹308.5 crore in the year-ago period.
At the operating level, EBITDA was up 20.2% to ₹90 crore in the second quarter of this fiscal over ₹74.8 crore in Q2 of the previous fiscal.
Also Read: Fortis Healthcare Q2 Results | Revenue rises 12%, net profit up marginally
The EBITDA margin stood at 25.7% in Q2 FY25 versus 24.3% in the prior-year period. EBITDA is earnings before interest, tax, depreciation, and amortisation.
"Consistent performance was driven by sustained growth in patient volumes and test volumes, which stood at 7% and 8%, respectively for the quarter. There was an increase in revenue per patient by 6%," Metropolis Healthcare said.
Ameera Shah, Executive Chairperson and Whole-time Director of Metropolis Healthcare said, "We are delighted to share that Q2 FY25 has been a successful quarter, marked by a significant increase in revenue, driven by strong profit after tax (PAT) growth and solid execution from our management team."
Also Read: PFC Q2 Results | Net profit up 9% to ₹7,215 crore, revenue rises 15%; declares dividend
"We have consistently achieved substantial growth, with revenue increasing by 13.4% and EBITDA rising by 22.2% year-on-year. This strong performance has been fuelled by a 21% YoY growth in B2C revenue, along with expansion in tier 3 cities and an improvement in our average revenue per patient. Key growth areas, including our specialty and TruHealth segments, have also contributed significantly," Surendran Chemmenkotil, Chief Executive Officer, of Metropolis Healthcare, said.
Also Watch | Surendran Chemmenkotil, CEO of Metropolis Healthcare discuss Q2 FY25 figures in an interview with CNBC-TV18.
The results came after the close of the market hours. Shares of Metropolis Healthcare Ltd ended at ₹2,116.95, up by ₹4.35, or 0.21%, on the BSE.
Also Read: Whirlpool Q2 Results | Net falls 25% but revenue up 13%; co to hike fridge production
(Edited by : Shoma Bhattacharjee)
